Despite a series of innovative drug therapies (sacubitril, SGLT2 inhibitors, etc.)and medical devices (ICD and CRT), decompensated chronic heart failure (CHF) remains one of the major causes of mortality, morbidity, and rehospitalization especially in developed countries [1,2,3]. This evidence concerns the gene SLC5A2 and congestive heart failure.